Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
erlotinib (tarceva) (1 trial)
phytosome (1 trial)
Silibinin (1 trial)
Adenocarcinoma (Phase 2)
Adenocarcinoma of Lung (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Trials (1 total)
Trial APIs (3 total)